New hope for tough breast cancer: Triple-Drug combo trial opens
NCT ID NCT07161791
Summary
This study is testing whether combining three different types of drugs—an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and chemotherapy—can help control advanced triple-negative breast cancer. The trial will enroll 12 women who have already received first-line treatment with immunotherapy. Researchers will measure how well the combination shrinks tumors and controls cancer growth over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.